A Study of Pembrolizumab and Ziv-aflibercept for Treating Patients with Advanced Solid Tumours

Trial ID: NCT02298959
Kidney Cancer Type: Any

Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targetting a molecule called PD-1 to reactivate the body’s own immune response to target and destroy cancer cells.

Ziv-aflibercept (Zaltrap®) is a type of tyrosine kinase inhibitor (TKI) that prevents the growth of cancer cells by blocking the formation of new blood vessels in tumours. It is similar to already approved medications such as Sunitinib (Sutent®), Pazopanib (Votrient®), and Axitinib (Inlyta®).

The Trial:
This study will investigate the safety and effectiveness of Pembrolizumab in combination with Ziv-aflibercept.

Different doses of each drug will be used to determine the optimal dosage.

Basic Eligibility:

  • All subtypes eligible
  • Advanced kidney cancer that cannot be removed by surgery
  • At least 1 prior treatment with a TKI therapy

Additional eligibility criteria will apply. Please speak to your doctor.

Find out more about this study.
Hospital / Cancer CentrePrincipal InvestigatorLocationTrial Status
Hospital / Cancer CentreBC Cancer - Vancouver Site Principal InvestigatorN/A LocationVancouver, BC Trial StatusActive, Not Recruiting
Hospital / Cancer CentrePrincess Margaret Cancer Centre Principal InvestigatorDr Philippe L. Bédard LocationToronto, ON Trial StatusSuspended
Do NOT follow this link or you will be banned from the site!